Abstract
Blinatumomab, a bispecific T-cell engager monoclonal antibody used to manage Philadelphia chromosome-negative relapsed or refractory B-cell precursor acute lymphoblastic leukemia (ALL) can be used to treat patients by inducing graft versus leukemia reaction post allogeneic hematopoietic stem cell transplantation, a feature which it was post allogeneic bone marrow transplantation, a feature which this drug was not aimed to do.
Document Type
Article
Publication Date
8-5-2016
Digital Object Identifier (DOI)
https://doi.org/10.1002/ccr3.604
Repository Citation
Khan, Muhammad Waqas and Gul, Zartash, "Blinatumomab May Induce Graft Versus Host Leukemia in Patients with Pre-B ALL Relapsing After Hematopoietic Stem Cell Transplant" (2016). Internal Medicine Faculty Publications. 103.
https://uknowledge.uky.edu/internalmedicine_facpub/103
Notes/Citation Information
Published in Clinical Case Reports, v. 4, issue 8, p. 743-746.
© 2016 The Authors. Clinical Case Reports published by John Wiley & Sons Ltd.
This is an open access article under the terms of the Creative Commons Attribution License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.